Sharon McDonough-Means
Sharon McDonough-Means has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- James B. Adams
School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ 85281, USA
3 shared publications - David Quig
Doctor’s Data, St. Charles, IL 60174, USA
2 shared publications - Elizabeth Geis
School for Engineering of Matter, Transport & Energy, Arizona State University, Tempe, AZ 85287, USA
2 shared publications - Eva Gehn
Autism Research Institute, San Diego, CA, USA
2 shared publications - Jessica Mitchell
Southwest College of Naturopathic Medicine, Tempe, AZ 85282, USA
2 shared publications - Melissa Loresto
Autism/Asperger's Research Program, Arizona State University, Tempe, AZ, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 23 January 2017
- Published by Springer Nature in Microbiome
- Vol. 5 (1) , 1-16
Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study
Autism spectrum disorders (ASD) are complex neurobiological disorders that impair social interactions and communication and lead to restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. The causes of these disorders remain poorly understood, but gut microbiota, the 1013 bacteria in the human intestines, have been implicated because children with ASD often suffer gastrointestinal (GI) problems that correlate with ASD severity. Several previous studies have reported abnormal gut bacteria in children with ASD. The gut microbiome-ASD connection has been tested in a mouse model of ASD, where the microbiome was mechanistically linked to abnormal metabolites and behavior. Similarly, a study of children with ASD found that oral non-absorbable antibiotic treatment improved GI and ASD symptoms, albeit temporarily. Here, a small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children. MTT involved a 2-week antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant (FMT) using a high initial dose followed by daily and lower maintenance doses for 7–8 weeks. The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain. Improvements persisted 8 weeks after treatment. Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved 8 weeks after treatment ended. Bacterial and phagedeep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment. Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio among other taxa increased following MTT, and these changes persisted after treatment stopped (followed for 8 weeks). This exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least 8 weeks after treatment ended, suggesting a long-term impact. This trial was registered on the ClinicalTrials.gov, with the registration number NCT02504554
- 23 January 2017
- Published by Springer Nature in Microbiome
- Vol. 5 (1) , 1-16
Top Cited PapersOpen AccessMicrobiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study
Autism spectrum disorders (ASD) are complex neurobiological disorders that impair social interactions and communication and lead to restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. The causes of these disorders remain poorly understood, but gut microbiota, the 1013 bacteria in the human intestines, have been implicated because children with ASD often suffer gastrointestinal (GI) problems that correlate with ASD severity. Several previous studies have reported abnormal gut bacteria in children with ASD. The gut microbiome-ASD connection has been tested in a mouse model of ASD, where the microbiome was mechanistically linked to abnormal metabolites and behavior. Similarly, a study of children with ASD found that oral non-absorbable antibiotic treatment improved GI and ASD symptoms, albeit temporarily. Here, a small open-label clinical trial evaluated the impact of Microbiota Transfer Therapy (MTT) on gut microbiota composition and GI and ASD symptoms of 18 ASD-diagnosed children. MTT involved a 2-week antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant (FMT) using a high initial dose followed by daily and lower maintenance doses for 7–8 weeks. The Gastrointestinal Symptom Rating Scale revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain. Improvements persisted 8 weeks after treatment. Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly and remained improved 8 weeks after treatment ended. Bacterial and phagedeep sequencing analyses revealed successful partial engraftment of donor microbiota and beneficial changes in the gut environment. Specifically, overall bacterial diversity and the abundance of Bifidobacterium, Prevotella, and Desulfovibrio among other taxa increased following MTT, and these changes persisted after treatment stopped (followed for 8 weeks). This exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve GI and behavioral symptoms of ASD. Improvements in GI symptoms, ASD symptoms, and the microbiome all persisted for at least 8 weeks after treatment ended, suggesting a long-term impact. This trial was registered on the ClinicalTrials.gov, with the registration number NCT02504554
- Open Access
- 12 December 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 111
Effect of a vitamin/mineral supplement on children and adults with autism
Vitamin/mineral supplements are among the most commonly used treatments for autism, but the research on their use for treating autism has been limited.
- 12 December 2011
- Published by Springer Nature in BMC Pediatrics
- Vol. 11 (1) , 111
Open AccessEffect of a vitamin/mineral supplement on children and adults with autism
Vitamin/mineral supplements are among the most commonly used treatments for autism, but the research on their use for treating autism has been limited.
- Open Access
- 1 January 2011
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 8 (1) , 34
Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity
The relationship between relative metabolic disturbances and developmental disorders is an emerging research focus. This study compares the nutritional and metabolic status of children with autism with that of neurotypical children and investigates the possible association of autism severity with biomarkers.
- 1 January 2011
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 8 (1) , 34
Open AccessNutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity
The relationship between relative metabolic disturbances and developmental disorders is an emerging research focus. This study compares the nutritional and metabolic status of children with autism with that of neurotypical children and investigates the possible association of autism severity with biomarkers.